Kinnon joins PredictImmune having spent over 20 years in a number of executive positions in the US and is anticipated to drive the company's next phase of development, commercialisation and expansion.
Following a career start as an analytical chemist at Smithkline French and Beckman Research, a predecessor company of GlaxoSmithKline, Kinnon went on to hold leadership positions with Transgenomic, ZyGEM, Life Technologies, Guava Technologies, and Cellomics.
PredictImmune is developing tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing inflammatory bowel disease.
Based on research at Cambridge University, the company is developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007